Coherus Oncology, Inc. (CHRS)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

2Y 5Y 10Y All
Quarterly Annual TTM

Revenue Annual

0 200M 400M 600M FY12: 1.9M FY13: 2.8M FY14: 31.1M FY15: 30M FY16: 189.5M FY17: 1.6M FY18: 0 FY19: 356.1M FY20: 475.8M FY21: 326.6M FY22: 211M FY23: 257.2M FY24: 26.4M FY25: 42.2M FY13 FY15 FY17 FY19 FY21 FY23 FY25

Gross Profit Annual

0 150M 300M 450M FY19: 339M FY20: 438.2M FY21: 269M FY22: 141M FY23: 98.3M FY24: 17.7M FY25: 28.4M FY19 FY20 FY21 FY22 FY23 FY24 FY25

Operating Income Annual

-270M -180M -90M 0 90M 180M 270M FY12: -38.5M FY13: -36M FY14: -64.7M FY15: -219.1M FY16: -115.9M FY17: -232.1M FY18: -204.4M FY19: 107.8M FY20: 156.3M FY21: -263.9M FY22: -256.9M FY23: -203.2M FY24: -199.7M FY25: -181.1M FY13 FY15 FY17 FY19 FY21 FY23 FY25

Net Income Annual

-300M -200M -100M 0 100M 200M 300M FY12: -33M FY13: -53.6M FY14: -87.1M FY15: -223.3M FY16: -127.3M FY17: -238.2M FY18: -209.3M FY19: 89.8M FY20: 132.2M FY21: -287.1M FY22: -291.8M FY23: -237.9M FY24: 28.5M FY25: 168M FY13 FY15 FY17 FY19 FY21 FY23 FY25

Cost of Revenue Annual

0 60M 120M 180M FY19: 17.1M FY20: 37.7M FY21: 57.6M FY22: 70.1M FY23: 159M FY24: 8.7M FY25: 13.8M FY19 FY20 FY21 FY22 FY23 FY24 FY25

Operating Cash Flow Annual

-270M -180M -90M 0 90M 180M 270M FY12: -18.3M FY13: 15.4M FY14: -23.9M FY15: -108M FY16: -252.5M FY17: -200.3M FY18: -159.3M FY19: 28.4M FY20: 154.1M FY21: -37.4M FY22: -241.1M FY23: -174.9M FY24: -20.4M FY25: -138.5M FY13 FY15 FY17 FY19 FY21 FY23 FY25

Free Cash Flow Annual

-270M -180M -90M 0 90M 180M 270M FY12: -20M FY13: 15.1M FY14: -26.8M FY15: -114.2M FY16: -259.1M FY17: -204.9M FY18: -160.1M FY19: 26.5M FY20: 146.9M FY21: -38.7M FY22: -243.2M FY23: -175.2M FY13 FY15 FY17 FY19 FY21 FY23

Operating cash flow minus capital expenditure.

Shares Outstanding Annual

0 40M 80M 120M FY12: 5M FY13: 4.8M FY14: 8.5M FY15: 37.1M FY17: 53.1M FY18: 65M FY19: 73.2M FY20: 83.5M FY21: 75.4M FY22: 77.6M FY23: 94.2M FY24: 114.6M FY25: 117.1M FY12 FY14 FY17 FY19 FY21 FY23 FY25

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-24.00 -16.00 -8.00 0.00 8.00 16.00 24.00 Q4 '13: -15.85 Q1 '14: -18.74 Q2 '14: -21.90 Q3 '14: -17.46 Q4 '14: -15.25 Q1 '15: -10.44 Q2 '15: -6.04 Q3 '15: -6.11 Q4 '15: -5.99 Q1 '16: -6.44 Q2 '16: -6.60 Q3 '16: -3.07 Q4 '16: -3.43 Q1 '17: -3.30 Q2 '17: -2.66 Q3 '17: -5.42 Q4 '17: -4.51 Q1 '18: -3.71 Q2 '18: -3.31 Q3 '18: -3.09 Q4 '18: -3.12 Q1 '19: -2.67 Q2 '19: -1.67 Q3 '19: -0.17 Q4 '19: 1.19 Q1 '20: 1.96 Q2 '20: 2.34 Q3 '20: 2.04 Q4 '20: 1.61 Q1 '21: -1.24 Q2 '21: -2.34 Q3 '21: -3.16 Q4 '21: -3.85 Q1 '22: -2.72 Q2 '22: -2.97 Q3 '22: -3.59 Q4 '22: -3.76 Q1 '23: -3.48 Q2 '23: -3.32 Q3 '23: -2.62 Q4 '23: -2.60 Q1 '24: -0.73 Q2 '24: -0.35 Q3 '24: -0.03 Q1 '26: -1.42 Q2 '26: -4.12 Q3 '14 Q1 '16 Q3 '17 Q1 '19 Q3 '20 Q1 '22 Q3 '23 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.